South San Francisco, CA December 19, 2023 Press Release FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results If approved, Xolair would be the…
South San Francisco, CA December 4, 2023 Press Release Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation Phase III (INAVO120) results shows that inavolisib in combination…
South San Francisco, CA October 11, 2023 Press Release Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based…
South San Francisco, CA October 4, 2023 Press Release Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment RAINBOWFISH study met its primary endpoint with 80% of…
South San Francisco, CA October 2, 2023 Press Release Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous…
South San Francisco, CA September 30, 2023 South San Francisco Chamber of Commerce Genentech Goes to Town – Celebrating 30 Remarkable Years Our longstanding partnership with Genentech reaches a significant milestone this year—the 30th anniversary of ‘Genentech Goes to Town.’…
South San Francisco, CA September 6, 2023 Press Release Acceptance based on the Phase III COMMODORE 2 study, which demonstrated crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal hemoglobinuria (PNH) If approved, crovalimab will be the first…
South San Francisco, CA September 2, 2023 Press Release ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced setting About half…
South San Francisco, CA August 23, 2023 Press Release South San Francisco, CA — August 22, 2023 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it has been made aware of an…
South San Francisco, CA August 12, 2023 REEDLEY, CA – A LESSON TO BE LEARNED Many residents in South San Francisco have questioned the safety of the biolabs in our City as the numbers of life science developments continue to…